Updated:
Bio Engineering Capital
Bio Engineering Capital is a venture capital firm focused on the bioengineering sector. It invests in bioengineers and startups in medical AI/DX, regenerative...
Overview
Bio Engineering Capital is a venture capital firm focused on the bioengineering sector. It invests in bioengineers and startups in medical AI/DX, regenerative medicine, and fundamental research. The firm collaborates with academia and industry experts to support entrepreneurial ventures in the life sciences domain, founded in 2024 in Tokyo, Japan.
General information
Firm type
Private Equity
Year founded
2024
Location
Region
Asia
Country
Japan
City
Tokyo
Corporate office
Tokyo, Japan
Sector focus
Frequently asked questions
Which stages and geographies does Bio Engineering Capital target?
Bio Engineering Capital focuses on seed and Series A rounds, with selective follow-on participation. Its primary geography is Japan, where university spinouts and research-institution commercialization provide deal flow. The firm also evaluates opportunities in Southeast Asia and, in limited cases, US or European biotech startups seeking an Asia-Pacific commercial partner.
How is Bio Engineering Capital different from corporate venture arms active in Japanese biotech?
Unlike corporate venture arms tied to pharmaceutical or chemical conglomerates, Bio Engineering Capital operates without a parent company's strategic constraints. It can pursue pure financial returns in synthetic biology and bio-automation without requiring portfolio companies to fit a corporate roadmap. This independence allows for a concentrated, thesis-driven portfolio rather than opportunistic minority stakes.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: